Skip to content Skip to footer

Is Addiction Hereditary?

When you think about addiction, you likely wonder if your family history puts you at risk. The answer isn't straightforward, genetics account for 40-60% of addiction vulnerability, while your environment shapes the rest. Your DNA influences how your brain responds to substances, but it doesn't seal your fate. Understanding this genetic component reveals why addiction…

Read more

20 Innovative Digital Therapeutics Companies of 2025

20 Innovative Digital Therapeutics Companies of 2025 

Shots:   The integration of innovative technologies in healthcare, such as digital health platforms and AI-enabled applications, is transforming the way diseases are detected, diagnosed, treated, and prevented  The global Digital Health market is expected to reach $197.88B in 2025 and grow at a CAGR of 6.88%, reaching $258.25B by 2029  PharmaShots presents a concise report…

Read more

Regeneron at ASH’24: Aafia Chaudhry in a Stimulating Dialogue Exchange with PharmaShots 

Shots:   Recently, Regeneron presented Odronextamab’s data in treating patients with different B-NHL subtypes (OLYMPIA studies) and marginal zone lymphoma (ELM-2 study)  Aafia Chaudhry, Vice President, Global Program Head for Hematology-Oncology at Regeneron, discusses Odronextamab’s ongoing studies as monotherapy and in combination to treat various malignancies  Aafia shares the upcoming PDUFA date on July 30th for…

Read more

Q1 2025

PharmaShots’ Key Highlights of Second Quarter 2025 

Shots:    Q2’2025 highlights major acquisitions in the pharma and biotech industry along with collaboartion. The talk of the town remained Blueprint Medicines’ acquisition by Sanofi for ~$9.5B    The quarter highlighted Collaboartion, including Eli Lilly Enters a ~$1.4B Licensing Agreement with Sangamo Therapeutics for its STAC-BBB Capsid    PharmaShots brings the Quarterly digest compiling insights from…

Read more

Unlocking Approval: Christophe Piketty from Galderma in an Illuminating Conversation with PharmaShots 

Shots:   Backed by positive results from the P-III ARCADIA study, Galderma’s Nemluvio recently received approval from the US FDA for patients with moderate to severe atopic dermatitis  Nemluvio (nemolizumab) has previously been approved for the treatment of prurigo nodularis  Christophe Piketty, VP, Head of Innovation, Therapeutic Dermatology, Global Clinical Sciences, Galderma, highlighted insights from the…

Read more

10 Hidden Financial Risks Pharma Professionals Can’t Ignore

10 Hidden Financial Risks Pharma Professionals Can’t Ignore

Working in the pharmaceutical industry comes with great rewards—but it’s not without its financial blind spots. High income, stock options, consulting gigs, and regulatory risk make this a unique environment where professionals can be exposed without realizing it.  If you’re focused on research, development, or clinical work, it’s easy to overlook personal finance strategy. But…

Read more

The Evolving Role of Nurses in the Pharmaceutical Industry

The Evolving Role of Nurses in the Pharmaceutical Industry

In today’s rapidly changing healthcare world, nurses are stepping into roles that go far beyond traditional bedside care. With the healthcare system becoming increasingly interconnected and innovation reshaping how care is delivered, new opportunities are emerging that allow nurses to use their clinical expertise in areas once reserved for scientists, researchers, and corporate professionals. One…

Read more

Disease of the Month – Angina 

Shots:  Characterized by discomfort or pain in the chest, Angina develops when the heart does not receive adequate oxygen-rich blood  PharmaShots' Disease of the Month report aims to familiarize the general population with conditions impacting communities worldwide. The report outlines disease characteristics, types, symptoms, diagnosis, treatments, epidemiology, market size, clinical trial analysis, patient advocacy groups (PAGs),…

Read more